MedKoo Biosciences, Inc.
Tel:   +1-919-636-5577    Fax:   +1-919-980-4831    Email:   sales@medkoo.com
Search
Login Register
Search
MedKoo Cat#: 145774 | Name: Florzolotau

Description:

WARNING: This product is for research use only, not for human or veterinary use.

Florzolotau (18F-florzolotau) is a PET tracer developed for imaging tau protein aggregates in the brain, which are associated with neurodegenerative diseases like Alzheimer's, progressive supranuclear palsy (PSP), and corticobasal syndrome (CBS). It enables early detection and differentiation of tau-related pathology, revealing distinctive patterns in conditions like PSP and CBS.

Chemical Structure

Florzolotau
Florzolotau
CAS#1565797-16-1

Theoretical Analysis

MedKoo Cat#: 145774

Name: Florzolotau

CAS#: 1565797-16-1

Chemical Formula: C20H20FN3O2S

Exact Mass: 385.1300

Molecular Weight: 385.46

Elemental Analysis: C, 62.32; H, 5.23; F, 4.93; N, 10.90; O, 8.30; S, 8.32

Price and Availability

This product is currently not in stock but may be available through custom synthesis. To ensure cost efficiency, the minimum order quantity is 1 gram. The estimated lead time is 2 to 4 months, with pricing dependent on the complexity of the synthesis (typically high for intricate chemistries). Quotes for quantities below 1 gram will not be provided. To request a quote, please click the button below. Note: If this product becomes available in stock in the future, pricing will be listed accordingly.
Bulk Inquiry
Related CAS #
No Data
Synonym
Florzolotau;
IUPAC/Chemical Name
1-fluoro-3-((2-((1E,3E)-4-(6-(methylamino)pyridin-3-yl)buta-1,3-dien-1-yl)benzo[d]thiazol-6-yl)oxy)propan-2-ol
InChi Key
XXNYLYXTRMQXJS-ZUVMSYQZSA-N
InChi Code
1S/C20H20FN3O2S/c1-22-19-9-6-14(12-23-19)4-2-3-5-20-24-17-8-7-16(10-18(17)27-20)26-13-15(25)11-21/h2-10,12,15,25H,11,13H2,1H3,(H,22,23)/b4-2+,5-3+
SMILES Code
CNC1=CC=C(\C=C\C=C\C2=NC3=C(S2)C=C(OCC(O)CF)C=C3)C=N1
Appearance
To be determined
Purity
>98% (or refer to the Certificate of Analysis)
Shipping Condition
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition
Dry, dark and at 0 -4 C for short term (days to weeks) or -20 C for long term(months to years).
Solubility
To be determined
Shelf Life
>2 years if stored properly
Drug Formulation
To be determined
Stock Solution Storage
0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code
2934.99.9001
More Info

Preparing Stock Solutions

The following data is based on the product molecular weight 385.46 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
1: Tang Y, Li L, Hu T, Jiao F, Han L, Li S, Xu Z, Fan Y, Sun Y, Liu F, Yen TC, Zuo C, Wang J. In Vivo 18 F-Florzolotau Tau Positron Emission Tomography Imaging in Parkinson's Disease Dementia. Mov Disord. 2023 Jan;38(1):147-152. doi: 10.1002/mds.29273. Epub 2022 Nov 11. PMID: 36368769. 2: Liu FT, Li XY, Lu JY, Wu P, Li L, Liang XN, Ju ZZ, Jiao FY, Chen MJ, Ge JJ, Sun YM, Wu JJ, Yen TC, Luo JF, Zuo C, Wang J; Progressive Supranuclear Palsy Neuroimage Initiative (PSPNI). 18 F-Florzolotau Tau Positron Emission Tomography Imaging in Patients with Multiple System Atrophy-Parkinsonian Subtype. Mov Disord. 2022 Sep;37(9):1915-1923. doi: 10.1002/mds.29159. Epub 2022 Jul 21. PMID: 35861378. 3: Liu FT, Lu JY, Li XY, Jiao FY, Chen MJ, Yao RX, Liang XN, Ju ZZ, Ge JJ, Li G, Shen B, Wu P, Song J, Li J, Sun YM, Wu JJ, Yen TC, Luo JF, Zhao QH, Zuo C, Wang J; Progressive Supranuclear Palsy Neuroimage Initiative. 18 F-Florzolotau Positron Emission Tomography Imaging of Tau Pathology in the Living Brains of Patients with Corticobasal Syndrome. Mov Disord. 2023 Apr;38(4):579-588. doi: 10.1002/mds.29338. Epub 2023 Feb 7. PMID: 36750757. 4: Liu FT, Lu JY, Li XY, Liang XN, Jiao FY, Ge JJ, Wu P, Li G, Shen B, Wu B, Sun YM, Zhu YH, Luo JF, Yen TC, Wu JJ, Zuo CT, Wang J; Progressive Supranuclear Palsy Neuroimage Initiative (PSPNI). 18F-Florzolotau PET imaging captures the distribution patterns and regional vulnerability of tau pathology in progressive supranuclear palsy. Eur J Nucl Med Mol Imaging. 2023 Apr;50(5):1395-1405. doi: 10.1007/s00259-022-06104-0. Epub 2023 Jan 11. PMID: 36627498; PMCID: PMC10027831. 5: Lu J, Ju Z, Wang M, Sun X, Jia C, Li L, Bao W, Zhang H, Jiao F, Lin H, Yen TC, Cui R, Lan X, Zhao Q, Guan Y, Zuo C; Shanghai Memory Study (SMS). Feasibility of 18F-florzolotau quantification in patients with Alzheimer's disease based on an MRI-free tau PET template. Eur Radiol. 2023 Jul;33(7):4567-4579. doi: 10.1007/s00330-023-09571-7. Epub 2023 Apr 26. PMID: 37099173. 6: Tang G, Lu JY, Li XY, Yao RX, Yang YJ, Jiao FY, Chen MJ, Liang XN, Ju ZZ, Ge JJ, Zhao YX, Shen B, Wu P, Sun YM, Wu JJ, Yen TC, Zuo C, Wang J, Zhao QH, Zhang HW, Liu FT; Shanghai Memory Study (SMS) and Progressive Supranuclear Palsy Neuroimage Initiative (PSPNI). 18F-Florzolotau PET Imaging Unveils Tau Pathology in Dementia with Lewy Bodies. Mov Disord. 2025 Jan;40(1):108-120. doi: 10.1002/mds.30055. Epub 2024 Nov 18. PMID: 39555939. 7: Lu J, Clement C, Hong J, Wang M, Li X, Cavinato L, Yen TC, Jiao F, Wu P, Wu J, Ge J, Sun Y, Brendel M, Lopes L, Rominger A, Wang J, Liu F, Zuo C, Guan Y, Zhao Q, Shi K; Progressive Supranuclear Palsy Neuroimage Initiative (PSPNI). Improved interpretation of 18F-florzolotau PET in progressive supranuclear palsy using a normalization-free deep-learning classifier. iScience. 2023 Jul 20;26(8):107426. doi: 10.1016/j.isci.2023.107426. PMID: 37564702; PMCID: PMC10410511. 8: Lin HC, Lin KJ, Huang KL, Chen SH, Ho TY, Huang CC, Hsu JL, Chang CC, Hsiao IT. Visual reading for [18F]Florzolotau ([18F]APN-1607) tau PET imaging in clinical assessment of Alzheimer's disease. Front Neurosci. 2023 May 12;17:1148054. doi: 10.3389/fnins.2023.1148054. PMID: 37250400; PMCID: PMC10213356. 9: Hong J, Lu J, Liu F, Wang M, Li X, Clement C, Lopes L, Brendel M, Rominger A, Yen TC, Guan Y, Tian M, Wang J, Zuo C, Shi K; Progressive Supranuclear Palsy Neuroimage Initiative (PSPNI). Uncovering distinct progression patterns of tau deposition in progressive supranuclear palsy using [18F]Florzolotau PET imaging and subtype/stage inference algorithm. EBioMedicine. 2023 Nov;97:104835. doi: 10.1016/j.ebiom.2023.104835. Epub 2023 Oct 14. PMID: 37839135; PMCID: PMC10590768. 10: Miyamoto M, Okuyama C, Kagawa S, Kusano K, Takahashi M, Takahata K, Jang MK, Yamauchi H. Radiation dosimetry and pharmacokinetics of the tau PET tracer florzolotau (18F) in healthy Japanese subjects. Ann Nucl Med. 2023 May;37(5):300-309. doi: 10.1007/s12149-023-01828-x. Epub 2023 Mar 9. Erratum in: Ann Nucl Med. 2024 Apr;38(4):328. doi: 10.1007/s12149-024-01917-5. PMID: 36890399; PMCID: PMC10129982. 11: Liu FT, Lu JY, Li XY, Ge JJ, Sun YM, Yen TC, Jiao FY, Chen MJ, Zhao J, Yao RX, Tang G, Xu H, Lan XL, Lu J, Cui RX, Brendel M, Shi K, Guan YH, Rominger A, Wang J, Zuo CT; Progressive Supranuclear Palsy Neuroimage Initiative (PSPNI). Visual reading for [18F]Florzolotau Tau PET scans in progressive supranuclear palsy. Eur J Nucl Med Mol Imaging. 2025 Jan;52(2):586-598. doi: 10.1007/s00259-024-06923-3. Epub 2024 Oct 1. PMID: 39352424. 12: Yamauchi H, Kagawa S, Kusano K, Ito M, Okuyama C. Misery Perfusion and Tau Deposition in Atherosclerotic Major Cerebral Artery Disease: A 18F-Florzolotau Positron Emission Tomography Study. Stroke. 2022 Dec;53(12):e500-e503. doi: 10.1161/STROKEAHA.122.040493. Epub 2022 Nov 7. PMID: 36337055; PMCID: PMC9698085. 13: Ju Z, Li Z, Lu J, Jiao F, Lin H, Bao W, Li M, Wu P, Guan Y, Zhao Q, Zhang H, Jiang J, Zuo C. In Vivo Tau Burden Is Associated with Abnormal Brain Functional Connectivity in Alzheimer's Disease: A 18F-Florzolotau Study. Brain Sci. 2022 Oct 6;12(10):1355. doi: 10.3390/brainsci12101355. PMID: 36291289; PMCID: PMC9599090. 14: Li XY, Jiao FY, Yao RX, Ju ZZ, Chen MJ, Ge JJ, Li G, Sun YM, Wu P, Wu JJ, Yen TC, Zuo C, Wang J, Lu JY, Liu FT; Progressive Supranuclear Palsy Neuroimage Initiative (PSPNI). The Monoamine Oxidase-B Inhibitor Selegiline Does Not Affect 18 F-Florzolotau Uptake in Patients with Progressive Supranuclear Palsy: A Longitudinal Case Series. Mov Disord. 2023 Apr;38(4):705-707. doi: 10.1002/mds.29328. Epub 2023 Jan 27. PMID: 36707403. 15: Lin KJ, Huang SY, Huang KL, Huang CC, Hsiao IT. Human biodistribution and radiation dosimetry for the tau tracer [18F]Florzolotau in healthy subjects. EJNMMI Radiopharm Chem. 2024 Apr 2;9(1):27. doi: 10.1186/s41181-024-00259-x. PMID: 38563872; PMCID: PMC10987466. 16: Hirata K, Matsuoka K, Tagai K, Endo H, Tatebe H, Ono M, Kokubo N, Oyama A, Shinotoh H, Takahata K, Obata T, Dehghani M, Near J, Kawamura K, Zhang MR, Shimada H, Yokota T, Tokuda T, Higuchi M, Takado Y. Altered Brain Energy Metabolism Related to Astrocytes in Alzheimer's Disease. Ann Neurol. 2023 Sep 13. doi: 10.1002/ana.26797. Epub ahead of print. PMID: 37703428. 17: Li Q, Li H, Huang Z, Li Y, Cui R. A Peculiar Tau Accumulation Pattern Identified Via 18 F-Florzolotau PET Imaging in a Patient With Frontotemporal Dementia Caused by a Mutation in the MAPT Gene. Clin Nucl Med. 2024 Oct 1;49(10):995-996. doi: 10.1097/RLU.0000000000005377. Epub 2024 Jul 15. PMID: 39010313. 18: Miyamoto M, Okuyama C, Kagawa S, Kusano K, Takahashi M, Takahata K, Jang MK, Yamauchi H. Correction: Radiation dosimetry and pharmacokinetics of the tau PET tracer florzolotau (18F) in healthy Japanese subjects. Ann Nucl Med. 2024 Apr;38(4):328. doi: 10.1007/s12149-024-01917-5. Erratum for: Ann Nucl Med. 2023 May;37(5):300-309. doi: 10.1007/s12149-023-01828-x. PMID: 38451403; PMCID: PMC10955007. 19: Kubota M, Endo H, Takahata K, Tagai K, Suzuki H, Onaya M, Sano Y, Yamamoto Y, Kurose S, Matsuoka K, Seki C, Shinotoh H, Kawamura K, Zhang MR, Takado Y, Shimada H, Higuchi M. In vivo PET classification of tau pathologies in patients with frontotemporal dementia. Brain Commun. 2024 Mar 1;6(2):fcae075. doi: 10.1093/braincomms/fcae075. PMID: 38510212; PMCID: PMC10953627. 20: Wang M, Lu J, Zhang Y, Zhang Q, Wang L, Wu P, Brendel M, Rominger A, Shi K, Zhao Q, Jiang J, Zuo C. Characterization of tau propagation pattern and cascading hypometabolism from functional connectivity in Alzheimer's disease. Hum Brain Mapp. 2024 May;45(7):e26689. doi: 10.1002/hbm.26689. PMID: 38703095; PMCID: PMC11069321.

View History

Monoacetoacetin

Monoacetoacetin